Long-term efficacy and tolerance of efavirenz- and nevirapine-containing regimens in adult HIV type 1 Senegalese patients

AIDS Research and Human Retroviruses

Volumn 24, Issue 6, 2008, Pages 753-760

  De Beaudrap, Pierre ^a,b,c,d,i   Etard, Jean François ^d   Guèye, Fatou Ngom ^e   Guèye, Mandoumbe ^f   Landman, Roland ^g   Girard, Pierre Marie ^g   Sow, Papa Salif ^e   Ndoye, Ibrahima ^h   Delaporte, Eric ^d  

^a HOSPICES CIVILS DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

^c LABORATOIRE DE BIOMÉTRIE ET BIOLOGIE EVOLUTIVE   (France)

^d INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^e Fann University Teaching Hospital   (Senegal)

^f Military Hospital   (Senegal)

^g BICHAT HOSPITAL   (France)

^h National AIDS Program   (Senegal)

ⁱ Service de Biostatistique   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANEMIA; ARTICLE; CD4 LYMPHOCYTE COUNT; CONFOUNDING VARIABLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG ERUPTION; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG WITHDRAWAL; ETHNIC GROUP; FEMALE; FOLLOW UP; HAZARD RATIO; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERAMYLASEMIA; LEUKONEUTROPENIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SIDE EFFECT; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; TIME OF DEATH; TOXIC EPIDERMAL NECROLYSIS; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

EID: 45749116210     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0295     Document Type: Article

References (38)

1. Hammer SM, Saag MS, Schechter M, et al.: Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006;296:827-843.
2. Bartlett J, Fath M, DeMasi R, et al.: An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS 2006;20:2051-2064.
3. Bartlett JA, DeMasi R, Quinn J, Moxham C, and Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS 2001;15:1369-1377.
4. UNAIDS/WHO: Progress on global access to HIV antiretroviral therapy: An update on "3 by 5." UNAIDS/WHO, Geneva, Switzerland, 2005. http://www.who.int/3by5/fullreportJune2005.pdf.
5. Desclaux A, Ciss M, and Taverne B: Access to antiretroviral drugs and AIDS management in Senegal. AIDS 2003;17: S95-S101.
6. Djomand G, Roels T, and Ellerbrock T: Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire. AIDS 2003;17:S5-S15.
7. Weidle P, Malamba S, and Mwebaze R: Assessment of a pilot antiretroviral drug therapy programme in Uganda: Patients' response, survival, and drug resistance. Lancet 2002;360:34-40.
8. WHO: Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach. 2006 revised. Geneva, Switzerland, 2006. http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf.
9. Robbins GK, De Gruttola V, Shafer RW, et al.: Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003;349:2293-2303.
10. Staszewski S, Morales-Ramirez J, Tashima KT, et al.: Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999:341:1865-1873.
11. van Leeuwen R, Katlama C, Murphy RL, et al.: A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS 2003:17:987-999.
12. Podzamczer D, Ferrer E, Consiglio E, et al.: A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). Antiviral Ther 2002;7:81-90.
13. Landman R, Schiemann R, Thiam S, et al.: Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in Senegal. AIDS 2003;17:1017-1022.
14. Médecins Sans Frontières: Untangling the Web. Médecins Sans Frontières, Paris, France, 2006.
15. Manosuthi W, Sungkanuparph S, Vibhagool A, Rattanasiri S, and Thakkinstian A: Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naive patients with advanced HIV infection. HIV Med 2004;5:105-109.
16. van Leth F, Phanuphak P, Ruxrungtham K, et al.: Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: A randomised open-label trial, the 2NN Study. Lancet 2004;363:1253-1263.
17. Keiser P, Nassar N, White C, Koen G, and Moreno S: Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naive patients: A cohort study. HIV Clin Trials 2002;3:296-303.
18. van Leth F, Andrews S, Grinsztejn B, et al.: The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS 2005;19:463-471.
19. Desclaux A, Lanièce I, Ndoye I, and Taverne B: The Senegalese Antiretroviral Drug Access Initiative. An Economic, Social, Behavioural and Biomedical Analysis. Projects of the Agence Nationale de Recherche sur le Sida et les hépatites virales (ANRS), Paris, France; UNAIDS/WHO, Geneva, Switzerland, 2004.
20. Robins J, Hernan M, and Brumback B: Marginal structural models and causal inference in epidemiology. Epidemiology 2000;11:550-560.
21. Sterne J, Hernán M, Ledergerber B, et al.: Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: A prospective cohort study. Lancet 2005;366: 378-384.
22. Cole SR, Hernan MA, Robins JM, et al.: Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol 2003;158:687-694.
23. Canestri A, Ndir A, and Vray M: Long-term evaluation of d4T, dI and EFV in antiretroviral naive patients in Senegal. ANRS 12-06/IMEA 012 trial. Second IAS Conference on HIV Pathogenesis and Treatment. Paris, France, July 13-17, 2003.
24. Etard JF, Ndiaye I, and Thierry-Mieg M: Mortality and causes of death in adults receiving HAART in Senegal: A 7-year cohort study. AIDS 2006;20:1181-1189.
25. Laurent C, Diakhaté N, and Gueye F: The Senegalese government's highly active antiretroviral therapy initiative: An 18-month follow-up study. AIDS 2002;16:1363-1370.
26. CDC: 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992;41:1-19.
27. Robins J and Finkelstein D: Correcting for noncompliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics 2000;56:779-788.
28. Rubin D: Multiple Imputation for Nonresponse in Surveys. John Wiley & Sons, New York, 1987.
29. Therneau T and Grambsch P: Modeling Survival Data: Extending the Cox Model. Springer-Verlag, New York, 2000.
30. Fellay J, Boubaker K, Ledergerber B, et al.: Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 2001;358:1322-1327.
31. Clarke S, Harrington P, Barry M, and Mulcahy F. The tolerability of efavirenz after nevirapine-related adverse events. Clin Infect Dis 2000;31:806-807.
32. Montaner JS, Reiss P, Cooper D, et al.: A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA 1998;279:930-937.
33. Kappelhoff BS, van Leth F, Robinson PA, et al.: Are adverse events of nevirapine and efavirenz related to plasma concentrations? Antiviral Ther 2005;10:489-498.
34. Matthews GV, Sabin CA, Mandalia S, et al.: Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: A cohort study. AIDS 2002; 16:53-61.
35. Pulido F, Arribas JR, Miro JM, et al.: Clinical, virologic, and immunologic response to efavirenz- or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study). J Acquir Immune Defic Syndr 2004;35:343-350.
36. Phillips AN, Pradier C, Lazzarin A, et al.: Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients. AIDS 2001;15:2385-2395.
37. Tarwater P, Mellors J, Gore M, et al.: Methods to assess population effectiveness of therapies in human immunodeficiency virus incident and prevalent cohorts. Am J Epidemiol 2001;154:675-681.
38. Hogan J and Lancaster T: Instrumental variables and inverse probability weighting for causal inference from longitudinal observational studies. Stat Methods Med Res 2004;13:17-48.